Phase i-n trial of vacop-b + filgrastim (g-csf) support for hiv-related non-hodgkins lymphoma (nhl)

The incidence of NHL associated with HTV infection continues to rise despite advances in anti-retroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined. We performed a dose-escalation trial to determine the maximum tolerated doses (MTD) of etoposide (E) and doxorubicin (A) as part of a 12 week chemotherapy regimen VACOP-B supported by G-CSF in patients (pts) with AIDS-related NHL. Pts were age 18, …